3
Announcements
Trials
Browse
Landscape
Phase
Phase 4
1
Status
Recruiting
1
Sponsor Class
OTHER
19
INDUSTRY
9
NIH
2
OTHER_GOV
1
Study Type
Interventional
1
Sponsor
Cancer Type
Genitourinary
1
Conditions
Prostatic Neoplasms
1
Prostatic Hyperplasia
1
Interventions
acetyl-2-naphthylalanyl-3-chlorophenylalanyl-1-oxohexadecyl-seryl-4-aminophenylalanyl(hydroorotyl)-4-aminophenylalanyl(carbamoyl)-leucyl-ILys-prolyl-alaninamide
3
Zoledronic Acid
3
enzalutamide
2
Magnetic Resonance Spectroscopy
2
LHRH, Ac-Nal(1)-Cpa(2)-Trp(3)-Arg(6)-Ala(10)-
2
Androgen Antagonists
2
Abiraterone Acetate
2
darolutamide
1
apalutamide
1
abiraterone
1
Watchful Waiting
1
Videotape Recording
1
Urination
1
Ultrasound, High-Intensity Focused, Transrectal
1
Transurethral Resection of Prostate
1
Surveys and Questionnaires
1
Surgical Procedures, Operative
1
Single Photon Emission Computed Tomography Computed Tomography
1
Rehabilitation
1
Radiotherapy
1
Radiosurgery
1
Prednisone
1
Prednisolone
1
Positron Emission Tomography Computed Tomography
1
Multiparametric Magnetic Resonance Imaging
1
Metformin
1
Magnetic Resonance Imaging
1
Finasteride
1
Everolimus
1
Dutasteride
1
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
1 trials
Recent
Start date
Enrollment
OTHER_GOV
×
Prostatic Neoplasms
×
Dutasteride
×
Clear all
NCT06001619
2023-08-21
PROMED
Turku University Hospital
Phase 4
Recruiting
100 enrolled